• EN
  • 登录
访问量：   最后更新时间：--

侯鹏

博士生导师
硕士生导师
教师姓名：侯鹏
电子邮箱：
性别：男
在职信息：在职
所属院系：第一附属医院
学科：临床医学
同学科/专业博导 同学科/专业硕导
Selected Publications
当前位置： 中文主页 > 研究成果 > Selected Publications

代表论文 (*通讯作者)：

  1. Dang H, Liu Y, Zhou Y, Sui M, Wang Y, Qiang W, Sui F, Zhang Y, Cao H, Wu X*, Ji M*, Hou P*. TET1 loss propels the development of hyperthyroidism by remodeling histone modifications of PAX8 promoter. Exp Mol Med. 2025 (In press, IF: 12.9)

  2. Gong L, Li S, Sun J, Liu R, Wang J, Wang S, Zhao Y, Yan L, Ji M, Yang D*, Hou P*, Liu D*. Targeted Degradation of Hexokinase 2 by A Novel Engineered Bispecific Chimeric Liposome-Based Nano-PROTACs for Enhancing Tumor Chemotherapy. Biomaterials. 2025; 326:123651. (IF: 12.9)

  3. Wei J, Liu Z, Zhang Y, Wang G, Cui X, Yu W*, Nie C*, Hou P*. Blocking interplay between TERT and c-Myc: a new therapeutic strategy for BRAFV600E/pTERT double mutated tumors. Int J Biol Sci. 2025; 21(11): 4961-4978. (IF: 10)

  4. Zhang H, Zeng Z, Liu Y, Zheng W, Wang J, Yao Y, Wang Y, Ji M*, Hou P*. Thyrotropin exacerbates insulin resistance by triggering macrophage inflammation in subclinical hypothyroidism. Exp Mol Med. 2025; 57(6):1246-1259. (IF: 12.9)

  5. Liu Z, Li Y, Wang S, Wang Y, Sui M, Liu J, Chen P, Wang J, Zhang Y, Dang C*, Hou P*. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. J Exp Clin Cancer Res. 2025 Feb 25;44(1):70. (IF: 12.8)

  6. Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y, Wang J, Ji M, Hou P*. Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. Int J Biol Sci. 2025; 21(4):1730-1748. (IF: 10)

  7. Liu Z, Zhang R, Bao Y, Chen Y, Zheng W, Yuan J, Zhang Z, Chen P, Ji M, Cheng Y*, Hou P*, Dang D, Ding D, Chen C*. Highly Efficient and Universal Degradation of PD-L1 via Mitochondrial Oxidative Stress Evoked by Cationic AIE-Active Photosensitizers for Cancer Immunotherapy. Adv Funct Mater. 2025, 35, 2414495. (IF: 19)

  8. Chen Y, Bao Y, Wang Y, Liu Z, Zheng W, Chen P, Wei W, Ji M, Zhang R, Hou P*, Chen C*. Alkyl chain engineering of ionic AIE molecules for developing superior self-adjuvanted nanovaccines in cancer immunotherapy. Chem Eng J. 2025; 506:159979. (IF: 13.2)

  9. Liu Y, Yuan M, Xu X, Yang H, Yao Y, Hou P*, Yu W*, Ji M*. USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. Int J Biol Sci. 2024; 20(13):5223-5238. (IF: 10)
  10. Wang S, Sui M, Chen Q, Guo J, Yang H, Zhou Y, Ji M, Cheng Y*, Hou P*. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy. Chem Eng J. 2024; 498:155074. (IF: 13.2)
  11. Sui M, Wang S, Zhou Y, Dang H, Zeng Z, Gu K, Cao H, Ji M, Dai P*, Cheng Y*, Hou P*. A tumor-responsive nanostrategy for reducing the risk of
    immunotherapy-related myocarditis. Chem Eng J. 2024; 494:153131. (IF: 13.2)
  12. Zhang R, Chen P, Wang Y, Zeng Z, Yang H, Li M, Liu X*, Yu W*, Hou P*. Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner. Int J Biol Sci. 2024; 20(12):4750-4766. (IF: 10)
  13. Zhou Y, Wang S, Guo J, Li C, Sui M, Zeng Z, Dang H, Gu Q, Zhu J*, Cheng Y*, Hou P*. Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. J Control Release. 2024; 374:489-504. (IF: 11.5)
  14. Zeng Z, Yang Z, Li C, Liu S, Wei W, Zhou Y, Wang S, Sui M, Li M, Lin S, Cheng Y, Hou P*. Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide-Drug Conjugates. J Med Chem. 2024; 67(21):19216-19233. (IF: 6.8)
  15. Lan X, Li H, Guo J, Feng C, Zhou X, Wang J, Li D, Ji M, Hou P*, Yang Q*. Lung-targeted delivery of nsp12 siRNAs restores host type I interferon responses. Chem Eng J. 2024; 491:151973. (IF: 13.2)

  16. Zhang Y, Liang L, Li H, Cao Y, Meng D, Li X, Wang M, Wang J, Yao Y, Zhang S, Chen C*, Hou P*, Yang Q*. Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy. Aggregate. 2024; e545.(IF: 13.7)

  17. Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J, Cao H, Li Y*, Ji M*, Hou P*. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023;55(8):1757-1769.  (IF: 12.9)

  18. Yang Q, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023; 42(20):1634-1648. (IF: 7.3)

  19. Zeng Z, Zheng W, Hou P*. The role of drug-metabolizing enzymes in synthetic lethality of cancer. Pharmacol Ther. 2022; 240:108219. (IF: 12.5)

  20. Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, Wang S, Zeng Z, Ji M*, Hou P*. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res. 2021; 40(1):387. (IF: 12.8)

  21. Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, Shi B, Yang J*, He N*, Hou P*. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021; 6(1):399. (IF: 52.7)

  22. Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M*, Hou P*. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28(8):2450-2464. (IF: 15.4)

  23. Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P*. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by improving hypoxic tumor microenvironment. J Nanobiotechnology. 2021;19(1):302. (IF: 12.6)

  24. Li Y#, Su X#, Feng C, Liu S, Guan H, Sun Y, He N*, Ji M*, Hou P*. CYP2S1 is a synthetic lethal target in BRAF V600E-driven thyroid cancers. Signal Transduct Target Ther. 2020;5(1):191. (IF: 52.7)

  25. He W#, Yan J#, Li Y, Yan S, Wang S, Hou P*, Lu W*. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics. J Control Release. 2020;325:293-303. (IF: 11.5)

  26. Li M#, Ruan B#, Wei J, Yang Q, Chen M, Ji M*, Hou P*. ACYP2 contributes to malignant progression of glioma through promoting Ca 2+ efflux and subsequently activating c-Myc and STAT3 signals. J Exp Clin Cancer Res. 2020; 39(1):106. (IF: 12.8)

  27. Ruan B, Liu W, Chen P, Cui R, Li Y, Ji M, Hou P*, Yang Q*. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation. Int J Biol Sci. 2020; 16(4):682-693. (IF: 10)

  28. Su X#, Shen Z#, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M*, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019; 9(15):4461-4473. (IF: 13.3)

  29. Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 15.7)

  30. He W#, Yan J#, Wang L, Lei B, Hou P*, Lu W*, Ma PX*. A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials. 2019; 206:13-24. (IF: 12.9)

  31. Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019; 38(24):4804-4819. (IF: 7.3)

  32. He W#, Wang S#, Yan J#, Qu Y, Jin L, Sui F, Li Y, You W, Yang G, Yang Q, Ji M, Liu M, Shao Y, Ma PX*, Lu W*, Hou P*. Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy. Adv Funct Mater. 2019; 29(10):1807736. (IF: 19)

  33. Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019; 38(3):345-359. (IF: 7.3)

  34. Bian Z#, Yan J#, Wang S#, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K*, Hou P*, He W*. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. Theranostics. 2018; 8(19):5320-5335. (IF: 13.3)

  35. He W#,*, Yan J#, Sui F#, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W, Shao Y*, Hou P*. Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy. ACS Nano. 2018;12(11):11664-11677. (IF: 16)

  36. Li Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. ZNF677 Suppresses Akt Phosphorylation and Tumorigenesis in Thyroid Cancer. Cancer Res. 2018; 78(18):5216-5228. (IF: 16.6)

  37. Qu Y, Shi B, Hou P*. Activated ERK: An Emerging Player in miRNA Downregulation. Trends in Cancer. 2017;3(3):163-165. (IF: 17.5)

  38. Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G*, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. (IF: 13.3)

  39. Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 13.8)

  40. Qu Y, Dang S, Hou P*. Gene methylation in gastric cancer. Clin Chim Acta. 2013 Sep 23;424:53-65. (ESI高被引论文)

  41. Hou P, Liu D, Shan Y, Hu S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. (IF: 10.2)

  42. Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216-8. (IF: 13.4)

  43. Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003; 31(16):e92. (IF: 13.1)

      其它SCI论文请链接http://www.ncbi.nlm.nih.gov/pubmed/?term=peng+hou

版权所有：西安交通大学 陕ICP备05001571号